Limits...
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Sankin A, Hakimi AA, Hsieh JJ, Molina AM - Front Oncol (2015)

Bottom Line: Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway.The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care.This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

View Article: PubMed Central - PubMed

Affiliation: Memorial Sloan-Kettering Cancer Center , New York, NY , USA.

ABSTRACT
Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

No MeSH data available.


Related in: MedlinePlus

Change in sum of longest tumor diameter. PR, partial response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4389537&req=5

Figure 3: Change in sum of longest tumor diameter. PR, partial response.

Mentions: This was the basis of a phase 2 trial conducted by Choueiri et al. that investigated the effect of foretinib (a dual MET/VEGFR inhibitor) in patients with metastatic papillary RCC (51). A total of 74 patients were enrolled in this trial. The overall response rate was 13% and median progression free survival was 9.3 months. Interestingly, patients with a germline or somatic c-Met alteration had a more drastic response to foretinib compared to those with wildtype c-Met (50 vs 9%, respectively) (Figure 3).


Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Sankin A, Hakimi AA, Hsieh JJ, Molina AM - Front Oncol (2015)

Change in sum of longest tumor diameter. PR, partial response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4389537&req=5

Figure 3: Change in sum of longest tumor diameter. PR, partial response.
Mentions: This was the basis of a phase 2 trial conducted by Choueiri et al. that investigated the effect of foretinib (a dual MET/VEGFR inhibitor) in patients with metastatic papillary RCC (51). A total of 74 patients were enrolled in this trial. The overall response rate was 13% and median progression free survival was 9.3 months. Interestingly, patients with a germline or somatic c-Met alteration had a more drastic response to foretinib compared to those with wildtype c-Met (50 vs 9%, respectively) (Figure 3).

Bottom Line: Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway.The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care.This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

View Article: PubMed Central - PubMed

Affiliation: Memorial Sloan-Kettering Cancer Center , New York, NY , USA.

ABSTRACT
Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data are currently available on the treatment of non-clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

No MeSH data available.


Related in: MedlinePlus